Following the termination of a multi-year collaboration with Takeda Pharmaceutical, Finch Therapeutics has regained the rights to two assets, FIN-524 and FIN-525, assessed for forms of inflammatory bowel disease.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,